Drug resistance and minimal residual disease in multiple myeloma

• Published in: Cancer drug resistance 2022-01, Vol.5 (1), p.171-183
• Main Authors: Gozzetti, Alessandro, Ciofini, Sara, Sicuranza, Anna, Pacelli, Paola, Raspadori, Donatella, Cencini, Emanuele, Tocci, Dania, Bocchia, Monica
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2578-532X; 2578-532X
• DOI: 10.20517/cdr.2021.116

Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However, the majority of MM patients do experience a relapse at a variable time after treatment, and ultimately the disease becomes drug-resistant following therapies. Recently, minimal residual disease (MRD) detection has been introduced in clinical trials utilizing novel therapeutic agents to measure the depth of response. MRD can be considered as a surrogate for both progression-free and overall survival. In this perspective, the persistence of a residual therapy-resistant myeloma plasma cell clone can be associated with inferior survivals. The present review gives an overview of drug resistance in MM, i.e., mutation of β5 subunit of the proteasome; upregulation of pumps of efflux; heat shock protein induction for proteasome inhibitors; downregulation of expression; deregulation of expression; mutation of , , and for immunomodulatory drugs and decreased target expression; complement protein increase; sBCMA increase; and BCMA down expression for monoclonal antibodies. Multicolor flow cytometry, or next-generation flow, and next-generation sequencing are currently the techniques available to measure MRD with sensitivity at 10 . Sustained MRD negativity is related to prolonged survival, and it is evaluated in all recent clinical trials as a surrogate of drug efficacy.